BioNexus (BGLC) Director Bin Azrul Receives 32,258-Share Award

What Happened

• Bin Abdul Hamid Muhammad Azrul, a director of BioNexus Gene Lab Corp. (BGLC), was granted a fully vested stock-based award of 32,258 shares on August 13, 2026. The award was issued under the BioNexus 2025 Equity Incentive Plan for no cash consideration and was valued for plan purposes at $1.55 per share (Nasdaq close on Aug 12, 2026), totaling approximately $49,999.90. This is an award/grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: August 13, 2026; Form 4 filed August 14, 2026 (timely; Form 4s are due within 2 business days).
• Transaction type/code: Award/Grant (A).
• Shares granted: 32,258; Plan valuation: $1.55 per share; total ≈ $49,999.90.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: Award is fully vested, granted for completed services, no cash consideration, under the 2025 Equity Incentive Plan (per filing footnote).

Context

• This was a compensation award for services, not a market purchase—such grants are routine forms of executive/director compensation and do not necessarily signal insider buying intent. Because the award was fully vested at grant, there is no vesting schedule tied to future service or performance in this entry.